A post on Fight Aging! (and a corresponding Nature article) argues that focusing on the brain alone may be a mistake. Blood-based protein signatures and the modest results of anti-amyloid drugs, it says, point to a body-wide problem.
The brain doesn’t work alone
In a commentary published on 21 September 2026, Reason, the author behind Fight Aging!, makes a simple point: every tissue exchanges signals with every other tissue, and none of them works in isolation.
The brain is where the damage shows up in neurodegenerative disease, but it depends on a functioning circulatory system, on the kidneys to clear metabolic waste, and on the lymphatic system to drain cerebrospinal fluid. It can also be disrupted by chronic inflammatory signalling from elsewhere in the body, or by unwanted metabolites from the gut microbiota. Reason argues that this way of thinking looks a lot like the medicine practised by the longevity industry.
A disease with unfinished causes
To make the case, the post quotes a research paper (not named in the excerpt) on Alzheimer’s disease, which is characterised by amyloid-β and phospho-tau pathology and by the loss of synapses and neurons. The paper says the exact causal mechanisms remain unclear and that the changes in brain and body before diagnosis are poorly understood. Studies suggest progression involves complex interactions across genetic, metabolic, proteomic and physiological domains, but current approaches struggle to capture them.
Clues in the blood
The post highlights large plasma proteomic studies of dementia cohorts. These have found circulating protein signatures linked to neurodegeneration and shared across different conditions. The quoted authors say such signals are hard to square with a brain-only model. They fit better with a common breakdown in cellular clearance and energy regulation across the body.
Because these signatures can be detected in blood, they could in principle be measured routinely over time. That could allow researchers to track cellular dysregulation across a lifespan and find the windows of opportunity when intervention is most likely to change the course of disease.
What the drug trials suggest
The argument is reinforced by recent therapeutic trials. Anti-amyloid monoclonal antibodies clear a substantial amount of amyloid, yet slow clinical decline only modestly. If amyloid were the main driver, the quoted text reasons, effective clearance should produce a correspondingly large benefit. The gap suggests amyloid is one part of a broader, multifactorial process, and that treatments may need to address systemic dysfunction rather than a single downstream target.
Worth keeping in mind
This is a commentary built around a quoted paper, so it presents an argument, not new data. The excerpt gives no trial figures and names no specific study. The “systemic dysfunction” it describes is a proposed explanation, not a settled one. It also does not say amyloid is irrelevant, only that it may not be the whole story.
Original sources:
https://www.nature.com/articles/s43856-026-01831-z
Transparency Note: This article was prepared with the assistance of artificial intelligence technologies. Every piece is thoroughly reviewed and verified by our editorial team, who retain full responsibility for the final content.
Picture: Gemini AI